drugset / Trial / NCT01452451
Safety, Tolerability, Pharmacokinetics,Pharmacodynamics Study of LAPS-Exendin in Subjects of Type 2 Diabetes Mellitus
RandomizedParallel-groupTriple-blindTreatment
Summary
The purpose of this study is to investigate the safety and tolerability of repeated doses of HM11260C when given different regimens in subjects with type 2 diabetes mellitus (T2DM) on stable metformin monotherapy.
Timeline
- Start
- 2011-12
- Primary completion
- 2013-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Efpeglenatide | Peptide | 1 mg | Subcutaneous |
| Comparator | Efpeglenatide | Peptide | 2 mg | Subcutaneous |
| Comparator | Efpeglenatide | Peptide | 4 mg | Subcutaneous |
| Comparator | Efpeglenatide | Peptide | 8 mg | Subcutaneous |
| Comparator | Efpeglenatide | Peptide | 12 mg | Subcutaneous |
| Comparator | Efpeglenatide | Peptide | 16 mg | Subcutaneous |